drugset / Trial / NCT02735876
A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is evaluating the efficacy of acalabrutinib in combination with rituximab (Arm 1) versus ibrutinib (Arm 2) versus acalabrutinib (Arm 3) for the treatment of relapsed or refractory (R/R) mantle cell lymphoma (MCL).
Timeline
- Start
- 2016-05
- Primary completion
- 2020-06
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acalabrutinib | Small molecule | — | Oral |
| Comparator | Ibrutinib | Small molecule | — | Oral |
| Subject | Rituximab | Monoclonal antibody | — | Intravenous |